441 Studies Now Enrolling
A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two- Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults with Autism Spectrum Disorder
Y202
| Sponsor: | Yamo Pharmaceuticals |
| Enrolling: | Male and Female Patients |
| Clinic Visits: | 10 |
| IRB Number: | 8301 |
| U.S. Govt. ID: | NCT05067582 |
| Contact: | Suvekcha Bhattachan: 914-997-5587 / suvekcha.bhattachan@nyspi.columbia.edu |
Additional Study Information:
This study will examine the possible benefits of an investigational drug called L1-79 in adolescents and young adults (12-21 years) diagnosed with autism spectrum disorder (ASD). Participation would involve ten visits to the Center for Autism and the Developing Brain in White Plains, NY over a period of 32 weeks. This will allow the study team to assess participants general health, perform developmental testing and study related medical care. You will not have to pay for any study-related treatments, lab tests or assessments. You will also receive $75 in reimbursements for in clinic study visits.
This study is closed
